title: Idelalisib: a rare cause of enterocolitis.
abstract: Idelalisib is an oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, approved by FDA since July 2014 for the treatment of relapsed follicular B-cell non-Hodgkin lymphoma. Data from three phases of the study involving idelalisib demonstrate diarrhea (47%) to be the common adverse effect. The other side effects are pyrexia (28%), fatigue (30%), nausea (29%), cough (29%), pneumonia (25%), abdominal pain (26%) and rash (21%). The characteristic histological findings of idelalisib colitis include intraepithelial lymphocytosis, neutrophilic cryptitis and epithelial cell apoptosis within the crypts. Histological findings help differentiate among other causes of diarrhea and entero-colitis. We present a female patient with recurrent follicular lymphoma treated with idelalisib and presented with diarrhea. She was found to have entero-colitis and was treated successfully with drug discontinuation and prednisone.
authors.affiliation: Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, USA.
authors.forename: Harika
authors.initials: H
authors.lastname: Balagoni
authors.affiliation: Department of Gastroenterology, James H. Quillen College of Medicine, East Tennessee State University, USA.
authors.forename: Dhara
authors.initials: D
authors.lastname: Chaudhari
authors.affiliation: Department of Gastroenterology, James H. Quillen College of Medicine, East Tennessee State University, USA.
authors.forename: Chakradhar
authors.initials: C
authors.lastname: Reddy
authors.affiliation: Department of Gastroenterology, James H. Quillen College of Medicine, East Tennessee State University, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Young
keywords: Idelalisib; diarrhea; enterocolitis